

PDMR Dealing

Oxford, UK - 22 August 2025: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that Kay Davies, a Non-Executive Director of the Company, purchased 4,563 shares at £4.36 per share on 11 August 2025 and disposed the same number (4,563) at £5.0040 per share on 18 August 2025.

The purchase of shares occurred during a closed period as a result of an administrative error by the PDMR's financial advisers. Accordingly, the transaction was executed on behalf of the PDMR without her immediate knowledge. The transaction was subsequently reversed, with the same number of shares sold as had originally been purchased. Upon being informed of the trade, the PDMR promptly escalated the matter to OXB, who in turn notified the FCA without delay.

As a gesture of goodwill, the PDMR has confirmed that any gains arising from the trade will be donated to a charity of their choice.

The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the transaction.

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")		
a)	Name	Kay Davies	
2.	Reason for the notification		
a)	Position/status	Non-Executive Director	
b)	Initial notification/ amendment	Initial Notification	
3.	Details of the Issuer		
a)	Full name of the entity	Oxford Biomedica plc	
b)	LEI code	213800S1GVQNXQ15K851	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Date of the transaction	2025-08-11	
b)	Description of the financial instrument	Ordinary Shares of 50 pence each	
c)	Identification code	ISIN: GB00BDFBVT43	
d)	Nature of the transaction	Purchase of Shares	
e)	Place of the transaction	London Stock Exchange, Main Market (XLON)	
f)	Currency	GBP - British pound	
g)	Price(s) and volumes(s)	Price(s)	Volume(s)
		£4.36	4,563
h)	Aggregated information		
	- Aggregate volume	4,563	
	- Price	£4.36	
	- Aggregated	£19,894.68	

	total	
--	-------	--

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")		
a)	Name	Kay Davies	
2.	Reason for the notification		
a)	Position/status	Non-Executive Director.	
b)	Initial notification/ amendment	Initial Notification	
3.	Details of the Issuer		
a)	Name	Oxford Biomedica plc	
b)	LEI code	213800S1GVQNXQ15K851	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Date of the transaction	2025-08-18	
b)	Description of the financial instrument	Ordinary Shares of 50 pence each	
c)	Identification code	ISIN: GB00BDFBVT43	
d)	Nature of transaction	Sale of shares	
e)	Place of the transaction	London Stock Exchange, Main Market (XLON)	
f)	Currency	GBP - British pound	
g)	Price(s) and volumes(s)	Price(s)	Volume(s)
		£5.0040	4,563
h)	Aggregated information		
	- Aggregate volume	4,563	
	- Price	£5.0040	
	- Aggregated total	£22,833.34	

-Ends-

Enquiries:

OXB:

Natalie Walter, Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

About OXB

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has 20 years of experience in viral vector, the driving force

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com, and follow us on [LinkedIn](#) and [YouTube](#).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHSEDFLEEISEDA